Craig Mitcham, DO
Ophthalmology · Kingsport, TNNPI 1841781127
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,238 of the $2,513 with a category attached, or 89.0%. 18 manufacturers reported payments, led by Alcon at 32.9% of the total. Reporting peaked in 2022 at $926 and has fallen 90.2% since, to $90 in 2025.
Across 53 payments — averaging $47.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$826
- AbbVie$433
- Ivantis, Inc$253
- Regeneron Healthcare Solutions, Inc.$187
- Microsurgical Technology, Inc.$152
- AstraZeneca$122
- plus $541 from 12 others
Across 4 payments — averaging $1016.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$4K
What the payments were for
- Speaking & faculty fees$321%
- Food & beverage$2,23889%
- Education$24310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 15 | $826 |
| AbbVie | 6 | $433 |
| Ivantis, Inc | 4 | $253 |
| Regeneron Healthcare Solutions, Inc. | 5 | $187 |
| Microsurgical Technology, Inc. | 1 | $152 |
| AstraZeneca | 1 | $122 |
| Sight Sciences, Inc. | 1 | $98 |
| Rxsight Inc | 3 | $73 |
| Genentech USA, Inc. | 3 | $68 |
| Amgen | 2 | $68 |
| Bausch & Lomb Americas Inc. | 3 | $63 |
| Glaukos Corporation | 2 | $49 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $27 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Duchesnay USA Incorporated | 1 | $20 |
| Tarsus Pharmaceuticals, Inc. | 1 | $16 |
| Dompe US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$523
- ARGOS$125
- DURYSTA$122
- EYLEA$122
- Centurion$112
How this compares
$2,513 in reported general payments places this provider in the 60th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $31,995 |
| XiidraLifitegrast | 17 | $22,279 |
| LumiganBimatoprost | 28 | $11,042 |
| Prednisolone Acetate | 61 | $1,916 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 41 | $1,864 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 142 | $1,777 |
| Latanoprost | 129 | $1,314 |
| Loteprednol Etabonate | 11 | $1,288 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $843 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $670 |
| Ketorolac Tromethamine | 22 | $499 |
| ValacyclovirValacyclovir Hcl | 14 | $238 |
| Doxycycline Hyclate | 16 | $131 |
| Timolol Maleate | 13 | $63 |
| Tramadol Hcl | 12 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $433 | $43,03758 claims |
| Bausch & Lomb Americas Inc.Xiidra | $63 | $22,27917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Kingsport
- Deborah ShermanNashville$3M
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian BiesmanNashville$630K
- Brian FowlerMemphis$206K
- Edward ChaumNashville$158K
- Brian JerkinsMemphis$150K
- James FreemanMemphis$141K
- Michael PattersonCrossville$138K
- John FreemanMemphis$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.